MoonLake Immunotherapeutics

NasdaqCM MLTX

MoonLake Immunotherapeutics Price to Book Ratio (P/B) on December 30, 2024: 6.53

MoonLake Immunotherapeutics Price to Book Ratio (P/B) is 6.53 on December 30, 2024, a -34.49% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

MoonLake Immunotherapeutics 52-week high Price to Book Ratio (P/B) is 11.05 on February 12, 2024, which is 69.06% above the current Price to Book Ratio (P/B).
MoonLake Immunotherapeutics 52-week low Price to Book Ratio (P/B) is 4.94 on June 21, 2024, which is -24.34% below the current Price to Book Ratio (P/B).
MoonLake Immunotherapeutics average Price to Book Ratio (P/B) for the last 52 weeks is 6.62.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

NasdaqCM: MLTX

MoonLake Immunotherapeutics

CEO	Dr. Jorge Santos da Silva
IPO Date	Oct. 20, 2020
Location	Switzerland
Headquarters	Dorfstrasse 29
Employees	50
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.

Key trends

Past 5 years